Yuki Noguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuki Noguchi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Goro Shibukawa
Department of Gastroenterology, Fukushima Medical University Aizu Medical Center, Fukushima, Japan
1 shared publication - Hidemichi Imamura
Department of Gastroenterology, Ohta Nishinouchi Hospital, Fukushima, Japan
1 shared publication - Hiroki Irie
Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
1 shared publication - Hiromasa Ohira
Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan
1 shared publication - Hiroyuki Asama
Department of Gastroenterology, Fukushima Red Cross Hospital, Fukushima, Japan
1 shared publication - Jun Nakamura
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan
1 shared publication
Latest Publications
- Open Access
- 6 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-6
Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan
Purpose: Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. Methods: We conducted a multicenter retrospective study. The primary endpoint was the overall survival (OS) of patients who underwent either S-1 monotherapy or FOLFOX after the onset of ILD. Toxicity data was also analyzed in the 2 groups. Results: Twenty-four patients were diagnosed with ILD and 17 patients who received subsequent chemotherapy were enrolled in the study. Among 17 patients who were managed with subsequent chemotherapy after recovering from ILD, we did not observe significant difference in OS between S-1 and FOLFOX (290.0 days vs. undefined, p = 0.39). Relapse of drug-induced ILD was not observed in all cases during the course. Overall, severe adverse events (CTCAE Grade 3 or 4) were observed in 3 patients (23.1%) in S-1 treatment group and 1 patient (25.0%) in FOLFOX treatment group (p = 0.93). Conclusions: S-1 monotherapy and FOLFOX are comparable as the subsequent chemotherapy after gemcitabine-based chemotherapy-induced ILD in unresectable PDAC.
- 6 April 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-6
Open AccessClinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan
Purpose: Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. Methods: We conducted a multicenter retrospective study. The primary endpoint was the overall survival (OS) of patients who underwent either S-1 monotherapy or FOLFOX after the onset of ILD. Toxicity data was also analyzed in the 2 groups. Results: Twenty-four patients were diagnosed with ILD and 17 patients who received subsequent chemotherapy were enrolled in the study. Among 17 patients who were managed with subsequent chemotherapy after recovering from ILD, we did not observe significant difference in OS between S-1 and FOLFOX (290.0 days vs. undefined, p = 0.39). Relapse of drug-induced ILD was not observed in all cases during the course. Overall, severe adverse events (CTCAE Grade 3 or 4) were observed in 3 patients (23.1%) in S-1 treatment group and 1 patient (25.0%) in FOLFOX treatment group (p = 0.93). Conclusions: S-1 monotherapy and FOLFOX are comparable as the subsequent chemotherapy after gemcitabine-based chemotherapy-induced ILD in unresectable PDAC.